MTX-531

MTX-531 is a first-in-class, orally available small molecule designed to selectively and potently inhibit both the epidermal growth factor receptor (EGFR) and phosphoinositide 3-kinase (PI3K), two critical kinases involved in cancer cell survival, proliferation, and resistance to therapy. Developed by MEKanistic Therapeutics, this dual kinase inhibitor was rationally engineered using computational chemistry approaches to overcome adaptive resistance mechanisms that limit the effectiveness of single-target therapies. Preclinical studies have demonstrated nanomolar potency against EGFR (IC50 = 14.7 nM) and PI3K (IC50 = 6.44 nM), with high selectivity across the kinome. Notably, unlike other pan-PI3K inhibitors, MTX-531 does not induce hyperglycemia in animal models—a side effect often limiting PI3K inhibitor use—likely due to its weak agonist activity at peroxisome proliferator-activated receptor gamma (PPARγ). In preclinical models of head and neck squamous cell carcinoma as well as KRAS-mutant colorectal and pancreatic cancers, MTX-531 monotherapy led to significant tumor regressions; combination with MEK or KRAS inhibitors further enhanced efficacy. The drug is currently in preclinical development for multiple solid tumors[1][2][4][5][6].